Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) mutations in the occurrence and treatment of pancreatic cancer.

Kirsten Rat Sarcoma Viral Oncogene Homologue(KRAS) mutations in the occurrence and treatment of pancreatic cancer. Curr Top Med Chem. 2019 Aug 28;: Authors: Zhu Z, Xiao S, Hao H, Hou Q, Fu X Abstract Pancreatic cancer is a highly malignant tumor with a 5-year survival rate of less than 6% and incidence increasing year by year in global. Pancreatic cancer has a poor prognosis and a high recurrence rate almost same as the death rate. However, the effective available prevention and treatment measures for pancreatic cancer were still limited. The genome variation is one of the main reasons for the occurrence and development of pancreatic cancer. In recent years, with the development of gene sequencing technology, deepening researches on pancreatic cancer gene mutation present that a growing number of genetic mutations were confirmed in a closely relationship with invasion and metastasis of pancreatic cancer. Among them, KRAS mutation is a special one. Therefore, it is particularly important to understand the mechanism of KRAS mutation in the occurrence and development of pancreatic cancer, and to explore the method of its transformation into clinical tumor molecular targeted treatment sites, to further improve the therapeutic effect of pancreatic cancer. Therefore, to better design chemical drugs, this review based on the biological functions of KRAS, summarized the types of KRAS mutations and their relationship with pancreatic cance...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research